Trevi Therapeutics (TRVI)

• Market cap: $1B
• 1 day: -15.38%
• 5 days: 17.69%
• 1 month: 12.55%
• 3 months: 33.71%
• 6 months: 30.95%
• Year to date: 89.22%
• 1 year: 150%
• 5 years: 113.73%
• 10 years: 4.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 33

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

110% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 31

109% more call options, than puts

Call options by funds: $7.77M | Put options by funds: $3.73M

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

13% more capital invested

Capital invested by funds: $554M [Q1] → $627M (+$72.8M) [Q2]

12% more funds holding

Funds holding: 137 [Q1] → 153 (+16) [Q2]

6.59% more ownership

Funds ownership: 91.16% [Q1] → 97.75% (+6.59%) [Q2]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18
• Avg. target: $23
• High target: $27

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Judah Frommer	$18	Overweight Initiated	21 Aug 2025
Raymond James Ryan Deschner	$27	Strong Buy Maintained	8 Aug 2025
Needham Serge Belanger	$22	Buy Maintained	8 Aug 2025
Cantor Fitzgerald Josh Schimmer	$25	Overweight Initiated	1 Jul 2025